AcelRx Pharmaceuticals (ACRX) Posts Narrower than Expected Q4 Loss of 33c/Share

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q4 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39).

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Union Pacific (UNP) Tops Q1 EPS by 18c
• Southern Copper Corp. (SCCO) Tops Q1 EPS by 20c
• Hertz Global (HTZ) misses earnings expectations as fleet costs weigh